SYMPTOMATIC EFFECT OF SELEGILINE IN DE-NOVO PARKINSONIAN-PATIENTS
SYMPTOMATIC EFFECT OF SELEGILINE IN DE-NOVO PARKINSONIAN-PATIENTS
复制标题
DOI：
10.1002/mds.870080508
复制
发表时间：
1993-01-01
影响因子：
8.6
通讯作者：
NEUKIRCH, HC
中科院分区：
文献类型：
--
作者：
ALLAIN, H;POLLAK, P;NEUKIRCH, HC
法国司来吉兰多中心试验于1990年进行，目的是研究在最初3个月内，司来吉兰（10 mg/天）单药治疗是否可以改善帕金森病初治患者的残疾。在来自13个中心的93名患者中进行了为期3个月的双盲、随机、安慰剂对照临床试验。采用Hoehn和Yahr、汉密尔顿抑郁量表、统一帕金森病评定量表、Schwab和England评分以及自我评估等多种疾病评定量表对症状进行评估。生物学和临床参数的耐受性进行了测量，疗效进行了调查，特别是在与L-多巴治疗开始的时间点。司来吉兰在各种运动评分上明显上级安慰剂，3个月结束时抑郁评分明显改善。不良反应罕见且轻微。因此，司来吉兰可能是治疗原发性帕金森病患者的首选疗法。
The French Selegiline Multicenter Trial was carried out in 1990 to investigate whether the disability of de novo patients with parkinsonism could be improved during the first 3 months by monotherapy with selegiline (10 mg/day). A double-blind, randomized, placebo-controlled clinical trial was conducted over 3 months with 93 patients from 13 centers. Symptomatology was assessed on various disease rating scales, including Hoehn and Yahr, Hamilton Depression Rating Scale, Unified Parkinson's Disease rating scale, and Schwab and England scores, as well as self-assessment. Biological and clinical parameters were measured for tolerability, and efficacy was investigated with special reference to the point at which therapy with L-dopa had to be started. Selegiline was significantly superior to placebo on the various motor rating scores, and depressive scores were significantly improved at the end of 3 months. Adverse effects were rare and minor. Therefore, selegiline could be the therapy of choice for the treatment of de novo parkinsonian patients.